
businessMay 1, 202654:13failed
E360: The Hardest Lessons I Learned from Building 4 Unicorns
About this episode
What if the biggest breakthroughs in biotech don’t come from more capital—but from building better systems for innovation?
In this episode, I sit down with Errik Anderson, biotech entrepreneur and founder behind multiple billion-dollar companies, to discuss how building infrastructure, not just drugs, is reshaping the future of healthcare. Errik explains why most biotech companies fail the same way, how reducing the cost and time of experimentation unlocks more innovation, and why staying private longer enables better long-term decision making. We also explore compounding in biotech, the limits of scaling creativity, and how conviction, mission, and talent ultimately determine which companies change the world.
Get every episode summarized
Each time How I Invest with David Weisburd publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from How I Invest with David Weisburd

E365: Stanford GSB Professor on Venture Capital’s Manager Incentives
How I Invest with David Weisburd
May 8, 202647:11pending

E364: $90B Limited Partner: Why We're (Still) Bullish on Large VC Funds
How I Invest with David Weisburd
May 7, 202639:19pending

E363: How Nigel Morris Built QED into a Fintech Powerhouse
How I Invest with David Weisburd
May 6, 202658:43pending

E362: Why Jensen Huang Believes Physical AI will be a $50 Trillion Market
How I Invest with David Weisburd
May 5, 202631:52pending